In order to inhibit the activity of the epidermal growth factor receptor (EGFR), anti-EGFR has been included in the therapeutic arsenal for patients with tumours of epithelial origin (lung and colorectal cancer) [14]. This evidence concerns the gene EGFR and neoplasm.